Clinical Trial Update: A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B [Phase 1]

View source ↗

Summary

Phase 1 study of the oral antiviral JNJ-440 to assess safety, tolerability, and pharmacokinetics after single ascending doses (with food effect), multi-day dosi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• JNJ-440

Snippet

Sponsor: Alios Biopharma Inc. | Conditions: Chronic Hepatitis B | Phase 1 | Status: COMPLETED